OncoBeta – epidermal radioisotope therapy

OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes.

We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188.
Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue.

Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects.

The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases.

We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.

Company’s Keywords:

nonmelanoma skin cancer treatment, brachytherapy, medical device, rhenium, basal cell carcinoma, squamous cell carcinoma, radioisotope, epidermal radioisotope therapy